<unk>  is used primarily for severe cystic acne and acne that has not responded to other treatments. Many dermatologists also support its use for treatment of lesser degrees of acne that prove resistant to other treatments, or that produce physical or psychological scarring.<unk>  is not indicated for treatment of prepubertal acne and is not recommended in children less than 12 years of age. It is also somewhat effective for hidradenitis suppurativa and some cases of severe rosacea. It can also be used to help treat harlequin ichthyosis, lamellar ichthyosis and is used in xeroderma pigmentosum cases to relieve keratoses.<unk>  has been used to treat the extremely rare condition fibrodysplasia ossificans progressiva. It is also used for the treatment of neuroblastoma, a form of nerve cancer.<unk>  therapy has furthermore proven effective against genital warts in experimental use, but is rarely used for this indication as there are more effective treatments.<unk>  may represent an efficacious and safe alternative systemic form of therapy for recalcitrant condylomata acuminata (RCA) of the cervix. In most countries this therapy is currently unapproved and only used if other therapies failed. Prescribing restrictions<unk>  is a teratogen; there is about a 20–35% risk for congenital defects in infants exposed to the drug in utero, and about 30–60% of children exposed to<unk>  prenatally have been reported to show neurocognitive impairment. Because of this, there are strict controls on prescribing<unk>  to women who may become pregnant and women who become pregnant while taking<unk>  are strongly advised to terminate their pregnancies. In most countries,<unk>  can only be prescribed by dermatologists or specialist physicians; some countries also allow limited prescription by general practitioners and family doctors. In the United Kingdom and Australia,<unk>  may be prescribed only by or under the supervision of a consultant dermatologist. Because severe cystic acne has the potential to cause permanent scarring over a short period, restrictions on its more immediate availability have proved contentious. In New Zealand,<unk>  can be prescribed by any doctor but subsidised only when prescribed by a vocationally-registered general practitioner, dermatologist or nurse practitioner. In the United States, since March 2006 the dispensing of<unk>  is run through a website called iPLEDGE. The FDA required the companies marketing the drug in the US, which at the time that iPLEDGE was launched were Roche, Mylan, Barr, and Ranbaxy, to put this website in place as a risk evaluation and mitigation strategy. These companies formed a group called the<unk>  Products Manufacturing Group, and it hired Covance to run the website. Prescribers, pharmacists, and all people to whom the drug is prescribed need to register on the site and log information into it. Women with child-bearing potential must commit to using two forms of effective contraception simultaneously for the duration of<unk>  therapy and for a month immediately preceding and a month immediately following therapy. Additionally, they must have two negative pregnancy tests 30 days apart and have negative pregnancy tests before each prescription is written.
Isotretinoin
Alitretinoin
Tretinoin
Clobetasol
Clobetasol propionate
Ulobetasol propionate
Ciclesonide
Tazarotene